Key result
DES ISR occurs in up to ~20% of patients and requires an algorithmic treatment approach.
Why the study?
The widespread implementation of drug-eluting stents and expanded percutaneous coronary intervention indications to high-risk patients and complex lesions introduced the clinical problem of drug-eluting stent in-stent restenosis.
Design
Review
Authors
Loading...
Supports algorithmic approach to symptomatic focal DES-ISR; leaves open optimal retreatment strategy pending randomized trials.
This review provides a comprehensive overview of the mechanisms, clinical presentation, and a proposed treatment algorithm for managing drug-eluting stent in-stent restenosis.
Dangas et al. (2010) conducted a review in Drug-eluting stent in-stent restenosis. Drug-eluting stent (DES) was evaluated. Drug-eluting stent in-stent restenosis occurs in 3% to 20% of patients, presenting predominantly as focal restenosis with recurrent angina, and requires an algorithmic approach for treatment.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: